Anti-Inflammatory Therapeutics Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 109.58 Bn

Forecast Year, 2035

USD 164.44 Bn

CAGR, 2026 - 2035

4.14%

Report Coverage

Global

What is the Anti-Inflammatory Therapeutics Market Size?

The global anti-inflammatory therapeutics market size is calculated at USD 109.58 billion in 2025 and is predicted to increase from USD 113.58 billion in 2026 to approximately USD 164.44 billion by 2035, expanding at a CAGR of 4.14% from 2026 to 2035.

Anti-Inflammatory Therapeutics Market Key Takeaways

• North America has captured the highest revenue share of over 37% in 2025.
• By drug class, the anti-inflammatory biologics segment holds the largest share of the market.
• By application, the autoimmune inflammatory illness segment dominated the market in 2025.
• By End-user, the hospital pharmacy segment is expected to grow at a significant rate during the forecast period.

Market Overview

Anti-inflammatory treatments aid in the reduction of both acute and chronic pain, such as that caused by sprains, menstrual pain, rheumatoid arthritis, migraines, and headaches. Compared to conventional medications, these therapies offer quicker relief. Additionally, they are able to lessen pain and swelling as well as prostaglandin levels and the substances that cause inflammation.

The alarming rise in autoimmune and respiratory disease incidence, the development of novel therapies, and the rapid uptake of anti-inflammatory medications are the main drivers propelling the growth of the worldwide anti-inflammatory market. Due to the development of anti-inflammatory biologics, which are more focused, effective, and have less adverse effects than traditional pharmaceuticals, the demand for anti-inflammatory medications has also been rising noticeably. Additionally, throughout the study period, it is anticipated that increased government activities to promote the use of nonsteroidal anti-inflammatory medications in Asia-Pacific and LAMEA would boost market growth. It is recognized that the patent expiration problems with blockbuster medications (like Remicade) and the negative effects of anti-inflammatory medications restrict the market's expansion.

Due to the inflammation brought on by SARS-COV 2, the COVID-19 pandemic is anticipated to have a beneficial effect on the market for anti-inflammatory therapeutics. Like COVID-19, SARS-CoV-2 is a beta coronavirus that can cause severe anti-inflammatory pneumonia in susceptible individuals. According to studies, cytokine storm has a significant role in these individuals' deaths. Acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes are a few of the side effects of severe inflammation and cytokine storms. As a result, research on and development of anti-inflammatory drugs for the treatment of inflammation brought on by COVID-19 have increased. For instance, several clinical trials are presently being conducted to reduce this harmful inflammation. The NLRP3 inflammasome is one of them; it targets a number of processes linked to COVID-19 excessive inflammation. Thus, amid the global health crisis, these variables have had a favourable effect on market growth.

Anti-Inflammatory Therapeutics Market Growth Factors

Increased government attempts to treat inflammation with non-steroidal anti-inflammatory medications in Asia-Pacific and LAMEA as well as rising public awareness of anti-inflammatory treatments are anticipated to fuel market expansion. As a result, this accelerates market expansion.

The market may expand as a result of the increased prevalence of chronic illnesses. In 2018, over 51.8% of individuals in the United States had at least one chronic ailment, while approximately 27.2% had several chronic disorders. Women, seniors 65 years of age and older, and residents of rural regions had the greatest incidence rates.

An increase in the prevalence of autoimmune and respiratory disorders, new medications under development, and a rise in the use of anti-inflammatory pharmaceuticals are all driving factors in the global market for anti-inflammatory treatments. The development of anti-inflammatory biologics, which are more targeted, efficient, and have less side effects than conventional pharmaceuticals, has also contributed to a considerable increase in the demand for anti-inflammatory medications. Additionally, growing public knowledge of anti-inflammatory treatments has a considerable impact on market expansion.

Market Outlook

• Industry Growth Overview: The industry is projected to see significant growth as more companies begin to manufacture and sell new types of biologics, biosimilars, and targeted therapies. This increase in growth will be fuelled by a greater awareness of the prevalence of chronic inflammations in today's society, as well as improved access to prescription medications among patients.
• Sustainability Trends: Many companies within the pharmaceutical industry are implementing environmentally friendly manufacturing processes, such as using recyclable packaging materials, and minimizing waste through recycling and reduction of chemicals.
• Global Expansion: As more regions of the world experience an increase in their healthcare spending due to economic development, they will also benefit from product localization and strategic partnerships that allow them to distribute advanced anti-inflammatory drugs into previously underserved geographic areas.
• Startup Ecosystem: The anti-inflammatory therapeutic market is seeing many innovative biotech startups emerge with new and unique inflammation-modulating technologies, as well as using AI-supported drug discovery models, and the development of immune-targeting therapeutics.

Market Scope

Market Dynamics

Key Market Drivers

Candidates for the pipeline that could boost the market

• Companies in this direction; Through the use of anti-tumor necrosis factor (TNF) inhibitors, interleukins, and other agents, the firms are concentrating on treating various inflammatory illnesses. For instance, UCB S.A. reported encouraging findings from the phase 3 clinical research of Bimekizumab for the treatment of psoriasis in December 2019. In addition, the market for anti-inflammatory medications is anticipated to be driven by research & development of NSAIDs and corticosteroids for the treatment of atopic dermatitis, plaque psoriasis, acute pain, and other conditions.

Increased inflammatory disease prevalence to benefit the market

• One of the key reasons fueling the growth of the anti-inflammatory therapies market is the increasing incidence of inflammatory disorders including psoriasis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel diseases, and others. By 2040, 78 million persons in the U.S. are anticipated to have arthritis that has been officially diagnosed by a doctor, according to the Centers for Disease Control and Prevention. This is anticipated to drive the market during the anticipated time frame. In addition, the market is anticipated to benefit from the increasing use of corticosteroids in the management of asthma and COPD as well as the rising incidence of atopic dermatitis.

Key Market Challenges

Side effects of anti-inflammatory drugs

• Anti-inflammatory medications suppress inflammation, which helps them lessen pain. These medications can reduce temperature, edoema, stiffness, and discomfort sensations. These medications' painkilling effects lessen inflammation's direct impact on pain-nerve activation and sensitivity as well as the indirect effects of anti-inflammatory heat, swelling in the knees, and joint pain.
• However, taking anti-inflammatory medications has potential adverse effects, which have become increasingly important over time. These medications' negative effects include fluid retention, decreased renal blood flow, and gastrointestinal bleeding. Additionally, eating them causes peptic ulcers, which are stomach ulcers.

Impending drug approvals

• Many medications or injections are now in the drug approval process. It is a highly time-consuming and difficult process to get regulatory approval for the medicine since regulatory agencies, like the U.S. FDA, impose onerous and onerous criteria on businesses engaged in the clinical research, marketing, manufacture, and distribution of drugs.

Key Market Opportunities

Introduction of innovative anti-inflammatory medications

• A major trend that is positively affecting the growth of the worldwide anti-inflammatory therapeutics market is the introduction of innovative anti-inflammatory medications. Immune cells create proteins called cytokines. These protein molecules let cells communicate with one another and are essential for cell growth and differentiation, including the control of the immune system. The JAK-inhibiting small compounds have been produced during the past few years, and many are currently undergoing clinical testing. The US FDA has authorised XELJANZ (tofacitinib) as the first small-molecule JAK pathway inhibitor for the treatment of moderately to severely active RA.

Segment Insights

Regional Insights

What is the U.S. Anti-Inflammatory Therapeutics Market Size?

The U.S. anti-inflammatory therapeutics market size is exhibited at USD 28.82 billion in 2025 and is projected to be worth around USD 46.17 billion by 2035, growing at a CAGR of 4.83% from 2026 to 2035.

In 2025, the North American region dominated the market for anti-inflammatory with a market share of 37.00%. The main causes of the market's rise in North America include rising demand for anti-inflammatory biologics, government backing for the introduction of biosimilars, and large research expenditures. The market will also benefit from rising sales of Humira, Ramicade, and Enbrel as well as advice from the Centers for Disease Control and Prevention about the use of non-opioid medications. Due to active government support for the introduction of biosimilars and attractive health reimbursement regulations, the market for anti-inflammatory medicines is anticipated to increase in Europe. Amgen announced the release of Amgevita, a biosimilar of adalimumab, in Europe in October 2018. It is predicted that this would help the European market.

---

Asia-Pacific Anti-Inflammatory Therapeutics Market Driven by Rising Disease Burden

An exponential rise in population, increased healthcare spending, and an increase in the prevalence of chronic, lifestyle-related, respiratory, and infectious illnesses are the main drivers of the anti-inflammatory therapeutic market in Asia-Pacific. Branded generics are gaining market share thanks to more effective therapy, strong marketing tactics, and promotions.

---

Europe Leads Innovation in Anti-Inflammatory Therapies

Europe is a highly developed region for anti-inflammatory therapies. Among other things, Europe has a large number of clinical trials and is very active in research and development (R&D) of new biologics, which help develop more effective therapies. The introduction of progressive reimbursement models in the region allows for diverse therapeutic options and a rapidly growing elderly population that is at a higher risk of developing inflammatory diseases. Major pharmaceutical companies are regularly releasing new treatments that further enhance Europe's innovative environment for developing treatments for inflammatory diseases.

---

Latin America Sees Rising Demand for Anti-Inflammatory Drugs

Latin America is experiencing a significant increase in anti-inflammatory drug usage due to the rising number of chronic pain, sports injuries and auto-immune disorders experienced by residents. Many Latin American countries have been improving their public health systems. The expansion of non-prescription (OTC) physical therapy is a contributing factor to the growth of this market. Pharmaceutical companies are expanding and strengthening their presence through regional partnerships and local manufacturing. Global pharmaceutical companies that have established anti-inflammatory drug manufacturing facilities are establishing Brazil and Mexico as their most attractive markets due to continued investments in the modernisation of healthcare systems within both countries.

---

Value chain Analysis

• Drug Discovery & Development: Companies such as Pfizer and Novartis focus significantly on developing biologics, immunotherapies and biosimilars designed to target inflammation at the cellular level as a way to enhance the effectiveness of precision medicine that has been available for years.
• Manufacturing and Quality Compliance: Manufacturers utilize advanced formulation technologies, sterile production processes and quality compliance systems to ensure that the products manufactured are safe, consistent and have received regulatory approval for global sales.
• Distribution & Commercialization: Retail pharmacies, online pharmacies, and hospitals coordinate their efforts to provide patients with easy access to medications and an extensive amount of marketing of their medications both through aggressive branding efforts and physician-facing promotional support.

Anti-Inflammatory Therapeutics Market Companies

• Eli Lily and Company
• AstraZeneca PLC, Amgen Inc.
• F. Hoffman, Abbvie, Inc.
• Johnson & Johnson
• GlaxoSmithKline
• Merck & CO., Inc.
• Novartis
• Pfizer, Inc.
• La Roche AG
• Ferring Pharmaceuticals
• Bioventus
• Zimmer Biomet Holdings, Inc.
• Flexion Therapeutics, Inc

Market Segmentation